Nature Reviews Gastroenterology &Hepatology最新文献

{"title":"Estimating dietary intake from human stool DNA","authors":"Katrina Ray","doi":"10.1038/s41575-025-01054-y","DOIUrl":"10.1038/s41575-025-01054-y","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 4","pages":"225-225"},"PeriodicalIF":45.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer","authors":"Katrina Ray","doi":"10.1038/s41575-025-01055-x","DOIUrl":"10.1038/s41575-025-01055-x","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 4","pages":"225-225"},"PeriodicalIF":45.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO’25","authors":"Eleni Kotsiliti","doi":"10.1038/s41575-025-01053-z","DOIUrl":"10.1038/s41575-025-01053-z","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 4","pages":"225-225"},"PeriodicalIF":45.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease","authors":"Nurulamin M. Noor, Shellie J. Radford, Babak Choodari-Oskooei, Morris Gordon, Ailsa L. Hart, Trish Hepburn, Ed Juszczak, James O. Lindsay, Nicholas A. Kennedy, Mahesh K. B. Parmar, Vipul Jairath, Gordon W. Moran","doi":"10.1038/s41575-025-01052-0","DOIUrl":"10.1038/s41575-025-01052-0","url":null,"abstract":"There is emerging interest in adaptive platform trials for inflammatory bowel disease. In this Comment, we present the results of a workshop that was convened to consider the opportunities and challenges of developing a platform trial in Crohn’s disease.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 6","pages":"364-366"},"PeriodicalIF":51.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research","authors":"Amira Metwaly, Aicha Kriaa, Zahra Hassani, Federica Carraturo, Celine Druart, IHMCSA Consortium, Kaline Arnauts, Paul Wilmes, Jens Walter, Stephan Rosshart, Mahesh S. Desai, Joel Dore, Alessio Fasano, Hervé M. Blottiere, Emmanuelle Maguin, Dirk Haller","doi":"10.1038/s41575-025-01041-3","DOIUrl":"10.1038/s41575-025-01041-3","url":null,"abstract":"The gut microbiome comprises trillions of microorganisms and profoundly influences human health by modulating metabolism, immune responses and neuronal functions. Disruption in gut microbiome composition is implicated in various inflammatory conditions, metabolic disorders and neurodegenerative diseases. However, determining the underlying mechanisms and establishing cause and effect is extremely difficult. Preclinical models offer crucial insights into the role of the gut microbiome in diseases and help identify potential therapeutic interventions. The Human Microbiome Action Consortium initiated a Delphi survey to assess the utility of preclinical models, including animal and cell-based models, in elucidating the causal role of the gut microbiome in these diseases. The Delphi survey aimed to address the complexity of selecting appropriate preclinical models to investigate disease causality and to study host–microbiome interactions effectively. We adopted a structured approach encompassing a literature review, expert workshops and the Delphi questionnaire to gather insights from a diverse range of stakeholders. Experts were requested to evaluate the strengths, limitations, and suitability of these models in addressing the causal relationship between the gut microbiome and disease pathogenesis. The resulting consensus statements and recommendations provide valuable insights for selecting preclinical models in future studies of gut microbiome-related diseases. In this Consensus Statement, causality, therapeutic applications and preclinical models in microbiome research are critically assessed, highlighting methodological approaches that enhance understanding. Gaps in current knowledge and practice are highlighted, and expert recommendations are given to advance microbiome research and its translation to clinical practice.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 5","pages":"343-356"},"PeriodicalIF":51.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41575-025-01041-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD","authors":"Marietta Iacucci, Yasuharu Maeda, Giovanni Santacroce, Subrata Ghosh","doi":"10.1038/s41575-025-01051-1","DOIUrl":"10.1038/s41575-025-01051-1","url":null,"abstract":"The AI-driven ‘endo-histo-omics’ approach integrates clinical, endoscopic, histological and molecular data to improve management of inflammatory bowel disease. This strategy enables precise patient stratification and outcome prediction, paving the way for advanced intestinal barrier assessment and restoration, thereby driving progress in personalized care.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 6","pages":"362-363"},"PeriodicalIF":51.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reframing obesity and MASLD","authors":"","doi":"10.1038/s41575-025-01046-y","DOIUrl":"10.1038/s41575-025-01046-y","url":null,"abstract":"As the burden of obesity and metabolic dysfunction-associated steatotic liver disease increases, the focus is shifting to the wide spectrum of disease, more accurate diagnostic criteria and the systems that influence our health to advance care.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 3","pages":"147-147"},"PeriodicalIF":45.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-025-01046-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143513881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine","authors":"Norbert Stefan, Giovanni Targher","doi":"10.1038/s41575-025-01048-w","DOIUrl":"10.1038/s41575-025-01048-w","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous disease regarding its pathophysiology and clinical outcomes. Two novel studies suggest that different clusters of people with MASLD exist, explaining part of this heterogeneity. These findings and future research applying data dimensionality reduction approaches might be beneficial for implementing precision medicine in MASLD.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 4","pages":"226-227"},"PeriodicalIF":45.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis","authors":"Jonas Wizenty, Michael Sigal","doi":"10.1038/s41575-025-01042-2","DOIUrl":"10.1038/s41575-025-01042-2","url":null,"abstract":"The demonstration that Helicobacter pylori is a pathogenic bacterium with marked carcinogenic potential has paved the way for new preventive approaches for gastric cancer. Although decades of research have uncovered complex interactions of H. pylori with epithelial cells, current insights have refined our view on H. pylori-associated carcinogenesis. Specifically, the cell-type-specific effects on gastric stem and progenitor cells deep in gastric glands provide a new view on the ability of the bacteria to colonize long-term, manipulate host responses and promote gastric pathology. Furthermore, new, large-scale epidemiological data have shed light on factors that determine why only a subset of carriers progress to gastric cancer. Currently, technological advances have brought yet another revelation: H. pylori is far from the only microorganism able to colonize the stomach. Instead, the stomach is colonized by a diverse gastric microbiota, and there is emerging evidence for the occurrence and pathological effect of dysbiosis resulting from an aberrant interplay between H. pylori and the gastric mucosa. With the weight of this evidence mounting, here we consider how the lessons learned from H. pylori research inform and synergize with this emerging field to bring a more comprehensive understanding of the role of microbes in gastric carcinogenesis. Helicobacter pylori has a role in gastric carcinogenesis, among other bacteria. This Review elucidates the role of pathogenic microbes in gastric cancer development and provides valuable insights into the underlying mechanisms.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 5","pages":"296-313"},"PeriodicalIF":51.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of biological sex in inflammatory bowel diseases","authors":"Diane M. Tshikudi, Charles N. Bernstein, Suresh Mishra, Jean-Eric Ghia, Heather K. Armstrong","doi":"10.1038/s41575-025-01038-y","DOIUrl":"10.1038/s41575-025-01038-y","url":null,"abstract":"The incidence of inflammatory bowel disease (IBD) has risen in the past decades and has emerged as a global health issue. IBD is characterized by chronic inflammation of the gastrointestinal tract. There is compelling evidence for the role of biological sex in IBD epidemiology, pathophysiology, disease progression, symptoms and extra-intestinal diseases. IBD disease course, management and therapies differ between men and women, yet there is a paucity of analysis of sex as a factor. This Review discusses the known influence of sex-linked genetic factors, hormones and hormone receptors in IBD incidence, prevalence, disease burden and clinical manifestation. Furthermore, we review the mechanisms underlying these sex-dependent effects on the dysregulation of gastrointestinal mucosal immunity (immune, epithelial barrier and microbiota) in IBD. To support the progressive inclusion of sex in the study of IBD, we summarize the current standard research methodology that should be implemented to investigate sex as a biological variable in IBD studies. Enhanced comprehension of the influence of sex in IBD pathophysiology will advance the development of targeted therapies and improve patient care. Biological sex has a vital role in the pathogenesis of inflammatory bowel disease (IBD). This Review examines sex in IBD pathophysiology and clinical manifestation and provides a frame for improving clinical and preclinical IBD studies by considering sex an essential factor.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 6","pages":"415-437"},"PeriodicalIF":51.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}